Janssen study shows benefits of new Darzalex regimen for multiple myeloma

Janssen has announced new clinical trial data that demonstrates the safety and efficacy of a new Darzalex-based combination regimen for multiple myeloma.

Results from the phase III ALCYONE study have shown that Darzalex, when used in combination with bortezomib, melphalan and prednisone (VMP), can significantly improve clinical outcomes in newly-diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation.

The new regimen was associated with meaningfully improved progression-free survival and response rates, including a 50 percent reduction in the risk of disease progression or death compared to VMP alone.

Janssen has already filed for US and European regulatory approval for this new indication of Darzalex, with the findings of the new study offering further evidence of its potential benefits.

Dr Sen Zhuang, vice-president of oncology clinical research at Janssen, said: "These latest results convey the promise of Darzalex in newly diagnosed patients, for whom the initial therapy is most critical for long-term survival."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.